Kirk Ramey v. Beta Bionics, Inc.

Summary

The United States District Court for the District of Massachusetts granted Beta Bionics, Inc.’s motion to dismiss claims arising from the alleged restriction on Kirk Ramey’s sale of shares following the company’s initial public offering. The court held that Ramey did not plausibly allege a breach of the settlement agreement or that the post-IPO lockup constituted an adverse claim under Massachusetts law. The court also dismissed the Massachusetts General Laws chapter 93A claim, without prejudice and with leave to amend.

Holdings

1. Ramey did not plausibly allege that Beta Bionics' post-IPO transfer restrictions constituted an adverse claim violating the settlement agreement. The agreement promised that the shares would be free of adverse claims when Ramey acquired them, and an adverse claim under Massachusetts law requires a property interest in the financial asset, not merely a contractual restriction or breach.
2. Ramey did not plausibly allege that Beta Bionics breached its promise to give his shares the same rights and restrictions as other Class B Common Stock. The complaint contained no well-pleaded facts showing that other stockholders were permitted to sell or transfer their shares during the lock-up period or were otherwise treated differently.
3. The chapter 93A claim failed because the complaint did not plausibly allege an underlying breach of contract and, independently, did not allege a knowing and extortionate breach intended to secure an unbargained-for benefit at Ramey's expense.

Questions Presented

1. Whether Ramey plausibly alleged that Beta Bionics breached the settlement agreement by imposing post-IPO transfer restrictions on his shares as an adverse claim.
2. Whether Ramey plausibly alleged that Beta Bionics breached the settlement agreement's promise that his shares would have the same rights and restrictions as other Class B Common Stock.
3. Whether Ramey stated a Massachusetts General Laws chapter 93A claim based on Beta Bionics' alleged breach and asserted purpose of protecting the company's enterprise value.

Disposition

other